Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish Merck as a global rival to Daiichi Sankyo and Ono Pharmaceutical in the indication.